血脂康对慢性心力衰竭患者TNF-a和IL-6及其血管内皮功能的影响

被引：0

作者：

彭艳

机构：

[1] 重庆医科大学

关键词：

血脂康; 慢性心力衰竭; 炎症; 内皮;

D O I：

暂无

年度学位：

2009

学位类型：

硕士

导师：

覃数;

摘要：

目的:观察血脂康短期治疗对胆固醇水平正常的慢性心力衰竭患者血清肿瘤坏死因子(TNF-α)、白介素6(IL-6)和肱动脉内皮功能的影响。探讨血脂康降低TNF-a和IL-6以及与改善慢性心力衰竭患者血管内皮功能的作用的关系。方法:48例慢性心衰患者(NYHA分级Ⅱ～Ⅳ级)随机分成血脂康组(n=24)和对照组(n=24)。两组均遵循慢性心力衰竭治疗指南给予常规治疗,血脂康组加用血脂康每次2粒,每日2次,共8周。测定治疗前后血清TNF-α、IL-6水平和肱动脉内皮功能。结果:1.血脂康组治疗后血清IL-6水平7.76±1.70 ng/L比治疗前12.78±1.83ng/L显著降低,有统计学意义(p＜0.01);与对照组治疗后水平9.79±1.89 ng/L比较,差异有统计学意义(p＜0.01)。 2.血脂康组治疗后TNF-α水平147.67±64.24 ng/L比治疗前227.21±73.16ng/L显著降低,有统计学意义(p＜0.01);与对照组治疗后水平186.33±76.56 ng/L比较,差异有统计学意义(p＜0.01)。 3.血脂康组治疗后反应性充血时的肱动脉内径较基础内径增加率13.67±2.45%比治疗前4.46±1.41%显著提高,有统计学意(P＜0.01);与对照组治疗后肱动脉内径较基础内径增加率8.37±2.57%比较,差异有统计学意义(P＜0.01)。 4.血脂康组治疗含服硝酸甘油后的肱动脉内径较基础内径增加率11.78±3.28%比治疗前11.07±2.16%,差异无统计学意义(P＞0.05);与对照组治疗后肱动脉内径增加率11.93±3.07%,差异无统计学意义(P＞0.05)。 5.血清TNF-α、IL-6与血管内皮依赖性舒张功能有相关性(r=0.325,p＜0.01;r=0.427,p＜0.01)。结论: 1.血脂康抑制慢性心力衰竭患者炎症因子TNF-α和IL-6的表达。 2.血脂康改善慢性心力衰竭患者的内皮依赖性血管舒张功能。 3.血脂康改善血管内皮依赖性舒张功能的作用可能与抑制TNF-α和IL-6有关。

引用

页数：41

共 27 条

[1]

Cytokines and acute heart failure.[J].David Chen;Christian Assad-Kottner;Carlos Orrego;Guillermo Torre-Amione.Critical Care Medicine.2008, 1 Su

[2]

Cytokine activation and disease progression in patients with stable moderate chronic heart failure [J].

Tanner, H. ;

Mohacsi, P. ;

Fuller-Bicer, G. A. ;

Rieben, R. ;

Meier, B. ;

Hess, O. ;

Hullin, R. .

JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2007, 26 (06) :622-629

[3]

Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure [J].

Sola, S ;

Mir, MQS ;

Lerakis, S ;

Tandon, N ;

Khan, BV .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (02) :332-337

[4]

Xuezhikang, an extract of cholestin, decreases plasma inflammatory markers and endothelin-1, improve exercise-induced ischemia and subjective feelings in patients with cardiac syndrome X [J].

Li, Jian-Jun ;

Wang, Ying ;

Nie, Shao-Ping ;

Li, Qian ;

Li, Yi-Shi ;

Huang, Yuan ;

Hui, Ru-Tai .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2007, 122 (01) :82-84

[5]

Statin use and survival in patients with chronic heart failure - results from two observational studies with 5200 patients [J].

Anker, Stefan D. ;

Clark, Andrew L. ;

Winkler, Ralf ;

Zugck, Christian ;

Cicoira, Mariantonietta ;

Ponikowski, Piotr ;

Davos, Constantinos H. ;

Banasiak, Waldemar ;

Zardini, Piero ;

Haass, Markus ;

Senges, Jochen ;

Coats, Andrew J. S. ;

Poole-Wilson, Philip A. ;

Pitt, Bertram .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2006, 112 (02) :234-242

[6]

The effects of Atorvastatin (10 mg) on systemic inflammation in heart failure [J].

Mozaffarian, D ;

Minami, E ;

Letterer, RA ;

Lawler, RL ;

McDonald, GB ;

Levy, WC .

AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (12) :1699-1704

[7]

Comparison of losartan and captopril on heart failure–related outcomes and symptoms from the losartan heart failure survival study (ELITE II).[J].Marvin A. Konstam;James D. Neaton;Philip A. Poole-Wilson;Bertram Pitt;Robert Segal;Divakar Sharma;Erik J. Dasbach;George W. Carides;Kenneth Dickstein;Günter Riegger;A. John Camm;Felipe A. Martinez;Deborah C. Bradstreet;Leila S. Ikeda;Emanuela P. Santoro.American Heart Journal.2005, 1

[8]

Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase [J].